美国HRRP目标内科疾病出院后30天内再就诊情况:全国回顾性分析
该研究为回顾性队列研究,纳入2012年1月1日至2015年10月1日美国联邦医疗保险按服务收费的65岁及以上患者因心力衰竭、急性心肌梗死或肺炎住院的3 038 740次索引住院。主要结局为出院后30天内总再就诊及分类型再就诊。结果显示,目标疾病每100例出院患者的总再就诊数每月增加0.023次(95%CI 0.010至0.035),其中急诊治疗即出院就诊每月增加0.023次(95%CI 0.015至0.032)、观察留观每月增加0.022次(95%CI 0.020至0.025),仅部分被再入院减少(-0.023,95%CI -0.035至-0.012)抵消。出院后30天内死亡率无显著变化(-0.0034,95%CI -0.012至0.0054)。作者认为,再入院减少可能源于医院和临床医生更多在急诊和观察留观中处理30天内返回的患者。
要点
- 2012年1月至2015年9月,HRRP目标疾病(心衰、急性心梗、肺炎)出院后30天内总再就诊数每月每100例出院增加0.023次(95%CI 0.010至0.035)。
- 再就诊增加由急诊治疗即出院(每月+0.023次/100例出院,95%CI 0.015至0.032)和观察留观(每月+0.022次/100例出院,95%CI 0.020至0.025)驱动。
- 同期再入院每月减少0.023次/100例出院(95%CI -0.035至-0.012),仅部分抵消总再就诊增加。
- 观察留观使用增加在非白人患者中比白人患者更明显。
- 出院后30天内目标疾病死亡率无显著变化(-0.0034,95%CI -0.012至0.0054)。
适用人群与场景
- 美国联邦医疗保险按服务收费、年龄65岁及以上、因心力衰竭、急性心肌梗死或肺炎住院的患者,索引住院时间为2012年1月1日至2015年10月1日。
研究设计与关键结果
- 研究类型为回顾性队列研究,纳入3 038 740次索引住院:心力衰竭1 357 620次、急性心肌梗死634 795次、肺炎1 046 325次。
- 每100例出院患者的总再就诊数每月增加0.023次(95%CI 0.010至0.035)。
- 急诊治疗即出院就诊每月增加0.023次/100例出院(95%CI 0.015至0.032),观察留观每月增加0.022次/100例出院(95%CI 0.020至0.025),再入院每月减少0.023次/100例出院(95%CI -0.035至-0.012)。
- 观察留观使用增加在非白人患者中比白人患者更明显。
- 出院后30天内目标疾病死亡率无显著变化(-0.0034,95%CI -0.012至0.0054)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,再入院减少可能源于医院和临床医生更多在急诊和观察留观中处理出院后30天内返回的患者,而非出院计划和照护过渡的改善。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine any changes in total hospital revisits within 30 days of discharge after a hospital stay for medical conditions targeted by the Hospital Readmissions Reduction Program (HRRP).
DESIGN: Retrospective cohort study.
SETTING: Hospital stays among Medicare patients for heart failure, acute myocardial infarction, or pneumonia between 1 January 2012 and 1 October 2015.
PARTICIPANTS: Medicare fee-for-service patients aged 65 or over.
MAIN OUTCOMES: Total hospital revisits within 30 days of discharge after hospital stays for medical conditions targeted by the HRRP, and by type of revisit: treat-and-discharge visit to an emergency department, observation stay (not leading to inpatient readmission), and inpatient readmission. Patient subgroups (age, sex, race) were also evaluated for each type of revisit.
RESULTS: Our study cohort included 3 038 740 total index hospital stays from January 2012 to September 2015: 1 357 620 for heart failure, 634 795 for acute myocardial infarction, and 1 046 325 for pneumonia. Counting all revisits after discharge, the total number of hospital revisits per 100 patient discharges for target conditions increased across the study period (monthly increase 0.023 visits per 100 patient discharges (95% confidence interval 0.010 to 0.035)). This change was due to monthly increases in treat-and-discharge visits to an emergency department (0.023 (0.015 to 0.032) and observation stays (0.022 (0.020 to 0.025)), which were only partly offset by declines in readmissions (-0.023 (-0.035 to -0.012)). Increases in observation stay use were more pronounced among non-white patients than white patients. No significant change was seen in mortality within 30 days of discharge for target conditions (-0.0034 (-0.012 to 0.0054)).
CONCLUSIONS: In the United States, total hospital revisits within 30 days of discharge for conditions targeted by the HRRP increased across the study period. This increase was due to a rise in post-discharge emergency department visits and observation stays, which exceeded the decline in readmissions. Although reductions in readmissions have been attributed to improvements in discharge planning and care transitions, our findings suggest that these declines could instead be because hospitals and clinicians have intensified efforts to treat patients who return to a hospital within 30 days of discharge in emergency departments and as observation stays.
参考来源
- Wadhera RK, Joynt Maddox KE, Kazi DS, et al. Hospital revisits within 30 days after discharge for medical conditions targeted by the Hospital Readmissions Reduction Program in the United States: national retrospective analysis. BMJ. 2019. PMID: 31405902. doi:10.1136/bmj.l4563
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。